CDK1 and pancreatic adenocarcinoma: Wijnen and colleagues also confirmed that CDK1 is a prognostic risk gene for pancreatic adenocarcinoma and suggested that the inhibition of CDK1 could be a new strategy for the treatment of pancreatic adenocarcinoma [21].